CEO Sets Strides For Growth With Endo Execs

Stelis Signals Listing, Focus Shift

 
• By Vibha Ravi

Appointing executives from Endo in key positions, Strides' CEO has set up a team to deliver growth, though the impact of ranitidine withdrawal and COVID-19 will defer a revenue target of $800m. Meanwhile, Stelis Biopharma signals a shift in focus from biologics development to CDMO opportunities and is poised for a stock exchange listing. 

A businessman appoints a leader to the head of the team. Creation of an effective teams of specialists for the implementation of a new project. HR recruiting. Management appointment. nepotism
Strides' CEO Has Set Up A High-Powered Team To Drive Growth • Source: Shutterstock

More from Earnings

More from Business